Vera Therapeutics, Inc. (VERA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth Win.
18/34
2.6 / 5 stars
All 34 Win/Lose results and 86 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 6 wins, 2 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
LoseVERA / S&P 6.66% / 15.20% |
No dataVERA / S&P / 15.00% |
WinVERA / S&P 63.69% / 50.40% |
| 2026-Q11/2 |
LoseVERA / S&P -20.56% / -4.33% |
No dataVERA / S&P / 11.30% |
WinVERA / S&P 84.67% / 27.70% |
| 2025-Q42/2 |
WinVERA / S&P 74.26% / 2.65% |
No dataVERA / S&P / 9.00% |
WinVERA / S&P 69.45% / 13.40% |
| 2025-Q32/2 |
WinVERA / S&P 23.34% / 8.12% |
No dataVERA / S&P / 4.61% |
WinVERA / S&P 52.87% / 13.45% |
| 2025-Q21/2 |
LoseVERA / S&P -1.92% / 10.94% |
No dataVERA / S&P / 4.83% |
WinVERA / S&P 61.99% / 10.63% |
| 2025-Q11/2 |
LoseVERA / S&P -43.20% / -4.27% |
No dataVERA / S&P / 4.98% |
WinVERA / S&P 46.34% / 10.57% |
| 2024-Q41/2 |
LoseVERA / S&P -4.32% / 2.41% |
No dataVERA / S&P / 5.25% |
WinVERA / S&P 20.09% / 6.15% |
| 2024-Q31/2 |
WinVERA / S&P 22.17% / 5.89% |
No dataVERA / S&P / 5.89% |
LoseVERA / S&P -10.00% / 6.11% |
| 2024-Q20/2 |
LoseVERA / S&P -16.09% / 4.28% |
No dataVERA / S&P / 5.38% |
LoseVERA / S&P -34.23% / 5.12% |
| 2024-Q11/2 |
WinVERA / S&P 180.36% / 10.56% |
No dataVERA / S&P / 5.71% |
LoseVERA / S&P -40.58% / 5.59% |
| 2023-Q41/2 |
WinVERA / S&P 12.18% / 11.69% |
No dataVERA / S&P / 6.81% |
LoseVERA / S&P -31.85% / 7.78% |
| 2023-Q30/2 |
LoseVERA / S&P -14.58% / -3.27% |
No dataVERA / S&P / 7.52% |
LoseVERA / S&P -7.64% / -5.03% |
| 2023-Q22/2 |
WinVERA / S&P 106.83% / 8.74% |
No dataVERA / S&P / 9.50% |
WinVERA / S&P 29.73% / -8.57% |
| 2023-Q11/2 |
LoseVERA / S&P -59.90% / 7.50% |
No dataVERA / S&P / 10.77% |
WinVERA / S&P 45.57% / -15.69% |
| 2022-Q40/1 |
LoseVERA / S&P -9.20% / 7.56% |
No dataVERA / S&P / 11.88% |
No dataVERA / S&P / -17.99% |
| 2022-Q31/1 |
WinVERA / S&P 56.58% / -4.88% |
No dataVERA / S&P / 13.47% |
No dataVERA / S&P / -1.41% |
| 2022-Q20/1 |
LoseVERA / S&P -42.06% / -16.10% |
No dataVERA / S&P / 13.71% |
No dataVERA / S&P / 11.04% |
| 2022-Q10/1 |
LoseVERA / S&P -12.09% / -4.60% |
No dataVERA / S&P / 15.97% |
No dataVERA / S&P / 42.23% |
| 2021-Q41/1 |
WinVERA / S&P 54.01% / 11.03% |
No dataVERA / S&P / 15.00% |
No dataVERA / S&P / 96.40% |
| 2021-Q31/1 |
WinVERA / S&P 30.84% / 0.58% |
No dataVERA / S&P / 10.77% |
No dataVERA / S&P / 69.42% |
| 2021-Q20/0 |
No dataVERA / S&P / 8.55% |
No dataVERA / S&P / 6.58% |
No dataVERA / S&P / 51.81% |
| 2021-Q10/0 |
No dataVERA / S&P / 6.17% |
No dataVERA / S&P / -1.06% |
No dataVERA / S&P / 7.39% |
| 2020-Q40/0 |
No dataVERA / S&P / 12.15% |
No dataVERA / S&P / -3.72% |
No dataVERA / S&P / -33.42% |
| 2020-Q30/0 |
No dataVERA / S&P / 8.93% |
No dataVERA / S&P / -2.04% |
No dataVERA / S&P / -27.10% |
| 2020-Q20/0 |
No dataVERA / S&P / 20.54% |
No dataVERA / S&P / -0.46% |
No dataVERA / S&P / -27.11% |
| 2020-Q10/0 |
No dataVERA / S&P / -19.60% |
No dataVERA / S&P / 3.47% |
No dataVERA / S&P / -14.75% |
| 2019-Q40/0 |
No dataVERA / S&P / 9.07% |
No dataVERA / S&P / 5.36% |
No dataVERA / S&P / 2.99% |
| 2019-Q30/0 |
No dataVERA / S&P / 1.70% |
No dataVERA / S&P / 5.02% |
No dataVERA / S&P / 0.21% |
| 2019-Q20/0 |
No dataVERA / S&P / 4.30% |
No dataVERA / S&P / 6.64% |
No dataVERA / S&P / 8.65% |
| 2019-Q10/0 |
No dataVERA / S&P / 13.65% |
No dataVERA / S&P / 8.12% |
No dataVERA / S&P / 14.29% |
| 2018-Q40/0 |
No dataVERA / S&P / -13.52% |
No dataVERA / S&P / 9.05% |
No dataVERA / S&P / 18.23% |
| 2018-Q30/0 |
No dataVERA / S&P / 7.71% |
No dataVERA / S&P / 10.21% |
No dataVERA / S&P / 19.06% |
| 2018-Q20/0 |
No dataVERA / S&P / 3.43% |
No dataVERA / S&P / 9.03% |
No dataVERA / S&P / 14.46% |
| 2018-Q10/0 |
No dataVERA / S&P / -0.76% |
No dataVERA / S&P / 7.68% |
No dataVERA / S&P / 12.46% |
| 2017-Q40/0 |
No dataVERA / S&P / 6.64% |
No dataVERA / S&P / 7.03% |
No dataVERA / S&P / 13.82% |
| 2017-Q30/0 |
No dataVERA / S&P / 4.48% |
No dataVERA / S&P / 5.68% |
No dataVERA / S&P / 17.57% |
| 2017-Q20/0 |
No dataVERA / S&P / 3.09% |
No dataVERA / S&P / 4.83% |
No dataVERA / S&P / 17.74% |
| 2017-Q10/0 |
No dataVERA / S&P / 6.07% |
No dataVERA / S&P / 3.67% |
No dataVERA / S&P / 13.32% |
| 2016-Q40/0 |
No dataVERA / S&P / 3.82% |
No dataVERA / S&P / 2.09% |
No dataVERA / S&P / 7.05% |
| 2016-Q30/0 |
No dataVERA / S&P / 3.85% |
No dataVERA / S&P / 0.20% |
No dataVERA / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VERA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 59.89% | 20.78% |
| Annualized return | 59.89% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VERA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 114.37% | 83.14% |
| Annualized return | 16.48% | 12.86% |
10Y · 2021-05-14 to 2026-08-27
| Metric | VERA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 200.87% | 319.30% |
| Annualized return | 11.64% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |